Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.

@article{Adjei2004PemetrexedA,
  title={Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.},
  author={Araba A. Adjei},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2004},
  volume={10 12 Pt 2},
  pages={4276s-4280s}
}
  • Araba A. Adjei
  • Published 2004 in
    Clinical cancer research : an official journal of…
Pemetrexed (ALIMTA, LY231514, MTA) is a novel antimetabolite that inhibits at least three enzymes involved in the folate pathway. These enzymes are thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed has demonstrated clinical activity in non-small cell lung cancer as well as in a broad array of other solid tumors, including mesothelioma, breast, colorectal, bladder, cervical, gastric and pancreatic cancer. In non-small cell lung cancer… CONTINUE READING